Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TroVax plus Docetaxel in mCRPC
NCT01194960Phase 2Terminated
- Sponsor
- Oxford BioMedica
- Start
- Aug 2010
- Primary completion
- Mar 2013
- Modality
- Oncolytic Viruses, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of MVA-5T4 in prostate cancer (PCa), sponsored by Oxford BioMedica. Started Aug 2010; status: terminated.
02
Drugs
MVA-5T4
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT01194960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01194960.